Apitegromab vs follistatin: the approved antibody vs the grey-market protein

Apitegromab and follistatin get mentioned in the same breath because both interrupt myostatin, the brake on muscle growth. That is where the similarity ends.

Apitegromab (sold as Isembyld) binds the inactive precursor forms of myostatin, promyostatin and latent myostatin, and stops them being activated. It only touches the myostatin pathway. It went through Phase 1, Phase 2 and Phase 3 trials and was approved by the FDA in September 2026 for spinal muscular atrophy, as an add-on for patients already on an SMN2-targeted therapy.

Follistatin binds mature myostatin and also activin A. It is a natural human glycoprotein, and the version sold to lifters is usually FST-344, the unprocessed gene-therapy precursor. No controlled trial has ever tested injected follistatin peptide for hypertrophy in healthy adults. The strongest follistatin evidence comes from AAV gene-therapy trials in muscular dystrophy, which is a different delivery method producing sustained expression, not a vial of peptide injected daily for ten days.

The practical comparison is not "which works better". It is that one is a hospital infusion you cannot get, and the other is a research reagent with a documented eye injury signal.

What they bind: Apitegromab binds only the inactive precursors of myostatin. Follistatin binds mature myostatin and activin A, so it also hits reproductive signalling, inflammation and possibly cardiac function.

Evidence level: Apitegromab has a Phase 3 trial in SMA and a Phase 2 in adults losing weight on tirzepatide. Follistatin has no controlled human trial for hypertrophy at all.

Does either build muscle in a healthy adult?: Neither has been shown to. Apitegromab has never been tested for it, and its Phase 1 in healthy volunteers had no muscle endpoint. Follistatin's hypertrophy case rests on animal myostatin-null models and gene-therapy trials, not on the injected peptide.

Route and access: Apitegromab is a 10mg/kg IV infusion given every 4 weeks in a clinic, available only on an SMA prescription at a reported 310,000 US dollars a year. Follistatin is a subcutaneous research peptide bought online with no prescription and no purity guarantee.

Documented harms: Apitegromab's label carries a fracture warning, 9 percent at the approved dose against 2 percent on placebo, plus animal bone findings and reproductive cautions. Follistatin has a retrospective case series of eleven bodybuilders on high-dose FST-344 who developed central serous chorioretinopathy, a fluid leak under the retina that degrades vision.

Half-life: Apitegromab follows antibody kinetics and is dosed monthly. Injected follistatin clears in roughly 3 to 4 hours, which is the core reason its hypertrophy case is weak: the blockade is not sustained.

Regulatory status: Apitegromab is approved in the US, withdrawn then being resubmitted in Europe over a manufacturing site issue, with no public Australian filing. Follistatin is approved nowhere for anything.

Neither is a muscle-building option for a healthy lifter, and that is the honest answer.

Apitegromab is relevant to you only if you or someone you know has spinal muscular atrophy and is already on nusinersen or risdiplam. There is no realistic off-label route, the cost is prohibitive, and it is a clinic-administered infusion.

Follistatin is obtainable, which is exactly the problem. It has no controlled efficacy evidence in healthy adults, an unresolved eye-injury signal at the doses people actually use, theoretical cancer concerns from chronic activin A and myostatin blockade, and highly variable product purity.

If your actual goal is keeping muscle while dieting on a GLP-1, the evidence-backed tools are resistance training through the deficit, protein intake held high while appetite is suppressed, a slower rate of loss, and measuring body composition rather than scale weight.